Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMGN NASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shs40 shsMLTXMoonLake Immunotherapeutics$51.89-1.6%$48.60$31.42▼$58.26$3.38B1.27537,532 shs296,159 shs10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMGNImmunoGen0.00%0.00%0.00%0.00%0.00%MLTXMoonLake Immunotherapeutics-1.65%+2.87%+10.99%+34.88%+20.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMGNImmunoGenN/AN/AN/AN/AN/AN/AN/AN/AMLTXMoonLake Immunotherapeutics2.6926 of 5 stars4.40.00.00.03.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMGNImmunoGen 0.00N/AN/AN/AMLTXMoonLake Immunotherapeutics 2.78Moderate Buy$74.4343.44% UpsideCurrent Analyst Ratings BreakdownLatest MLTX and IMGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025MLTXMoonLake ImmunotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$74.00 ➝ $82.007/28/2025MLTXMoonLake ImmunotherapeuticsRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold7/28/2025MLTXMoonLake ImmunotherapeuticsRothschild & Co RedburnSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$65.006/3/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.005/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMGNImmunoGen$287.61M28.91N/AN/A$0.71 per share43.99MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$5.59 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMGNImmunoGen-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/AMLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%N/ALatest MLTX and IMGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/A5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMGNImmunoGenN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMGNImmunoGen0.135.705.65MLTXMoonLake Immunotherapeutics0.2116.6521.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMGNImmunoGen90.50%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipIMGNImmunoGen5.07%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMGNImmunoGen277266.26 million252.76 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.32 millionOptionableMLTX and IMGN HeadlinesRecent News About These CompaniesMoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Raised to $82.00 at The Goldman Sachs GroupAugust 7 at 11:43 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Earnings Results, Misses Expectations By $0.14 EPSAugust 6 at 3:56 PM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Lifted by Westfield Capital Management Co. LPAugust 6 at 5:38 AM | marketbeat.comEnvestnet Asset Management Inc. Acquires 5,254 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)August 6 at 3:08 AM | marketbeat.comBeyond the Balance Sheet: What SWOT Reveals About MoonLake Immunotherapeutics (MLTX)August 5 at 12:18 AM | gurufocus.comMoonLake Immunotherapeutics: Buy Rating Driven by Promising SLK Phase 3 Data and Strong Financial PositionAugust 5 at 10:37 AM | tipranks.comMoonLake Immunotherapeutics Updates on Phase 3 VELA Program and Financial Results for Q2 2025August 5 at 7:19 AM | quiverquant.comQMoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business UpdateAugust 5 at 7:00 AM | globenewswire.comBIT Capital GmbH Has $571,000 Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)August 4, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Sells 5,351 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)August 3, 2025 | marketbeat.comAnalysts Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $73.14August 3, 2025 | americanbankingnews.comTD Asset Management Inc Sells 44,730 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)August 2, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Decreased by Federated Hermes Inc.August 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 31, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Projected to Post Quarterly Earnings on WednesdayJuly 30, 2025 | marketbeat.comPromising Outlook for MoonLake Immunotherapeutics: Buy Rating Backed by Strong Position in Hidradenitis Suppurativa TreatmentJuly 29, 2025 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to "Hold" at Redburn AtlanticJuly 29, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Now Covered by Analysts at Rothschild & Co RedburnJuly 29, 2025 | americanbankingnews.comMoonLake initiated with a Neutral at Rothschild & Co RedburnJuly 28, 2025 | msn.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Rothschild & Co RedburnJuly 28, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Receives Neutral Rating from RedburnJuly 28, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLTX and IMGN Company DescriptionsImmunoGen NASDAQ:IMGNImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.MoonLake Immunotherapeutics NASDAQ:MLTX$51.89 -0.87 (-1.65%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$52.25 +0.36 (+0.69%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
